Early-phase expansion in an age of cut backs
30 June 2011 | Jonathan Hare Scrip Clinical Research
BioNotebook: Seven public company funding updates, including Dendreon debt debacle and three IPO filings BioNotebook: Top five venture capital highlights; Sofinnova, Remiges, Atox, Cerecor, Synlogic Covidien's Q4 "choppy" but still in line Quintiles shuts Indian Phase I facility amid 'challenging environment'
Other Features & Analysis
Moses makes his mark EU medical device regulatory reform vote delay is a good thing Medtech VCs: assessing potential return on investment Why patient centricity is the only option in Horizon 2030